Navigation Links
Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
Date:3/24/2009

ALLEGAN, Mich., March 24 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration to market Sulfacetamide Sodium Topical Suspension, 10% (Lotion).

The product has been determined to be therapeutically equivalent (AB) to Sanofi-Aventis' Klaron(R) (Sodium Sulfacetamide) Lotion, 10%, which is indicated for the topical treatment of acne. Klaron(R) Lotion had sales of approximately $15 million for the 12 months ended January 2009, as measured by Wolters Kluwer Health.

Perrigo's Chairman and CEO Joseph C. Papa concluded, "This approval is another example of our commitment to invest in and bring new products to market. It further demonstrates our strategy to deliver quality affordable healthcare both behind and over the counter."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 28, 2008, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Begins Shipments of Ibuprofen PM
2. Perrigo Reports Record Second Quarter Sales
3. Perrigo Company Announces Quarterly Dividend
4. Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals
5. Perrigo Company Will Release Second Quarter Fiscal Year 2009 Results on February 3, 2009
6. Perrigo Company to Present at the 27th Annual JPMorgan Healthcare Conference
7. Perrigo Announces FDA Final Approval for Ibuprofen PM
8. Perrigo Settles Desloratadine Patent Litigation
9. Perrigo Acknowledges Settlement of NASACORT(R) AQ Nasal Spray Patent Litigation
10. Perrigo Announces FDA Tentative Approval for Ibuprofen PM
11. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... , ... June 28, 2017 , ... With the onset of long work hours and ... fractures due to falls at work and at home will only continue to grow unless ... are not following proper safety procedures, a fall at work or home can lead to ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... technology makes it possible to see through objects, has announced the winners of ... consumer apps with its fully programmable, Raspberry Pi-enabled 3D sensor, Walabot . ...
(Date:6/28/2017)... ... , ... As we celebrate our nation’s independence, many Americans will gather around ... time to celebrate National Hot Dog Month. The National Hot Dog and Sausage ... 4th alone and while they enjoy many different kinds of hot dogs, research commissioned ...
(Date:6/28/2017)... ... 2017 , ... Quorum Health announced that Robert A. Vento has been appointed ... Maher was promoted to COO of QHR. , A national search was ... and CEO in December 2016. , “I’m pleased to announce these ...
(Date:6/28/2017)... ... June 28, 2017 , ... The parent company ... in employee engagement. Omaha-based C&A Industries, a national leader in staffing and ... in North America for 2017. The annual award, issued by Achievers, ...
Breaking Medicine News(10 mins):
(Date:6/27/2017)... , June 27, 2017  Therapix Biosciences Ltd. (Nasdaq: ... company specializing in the development of cannabinoid-based drugs, today ... Market Opening Bell in New York, NY ... of its initial public offering (IPO) of American Depository ... March 2017. Dr. Elran Haber, Ph.D., Chief ...
(Date:6/27/2017)... BEACH, Calif. , Jun 27, 2017   NuEyes ... a round of funding to fuel its growth in helping ... ODG (Osterhout Design Group), the leading developer of ... which NuEyes technology sits. The undisclosed funding amount ... venture capital firm, Arab Angel, with offices in ...
(Date:6/20/2017)... and LAGUNA HILLS, Calif. , June ... new data that validate the use of MMprofiler with ... with multiple myeloma (MM). In a poster presentation at ... Association (EHA) in Madrid, Spain , ... for identifying high-risk elderly patients. In ...
Breaking Medicine Technology: